Get the Stockscreener App
1.10
0.92%
0.01
Scinai Immunotherapeutics Ltd Adr stock is traded at $1.10, with a volume of 47,276.
It is up +0.92% in the last 24 hours and up +56.36% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
See More
Previous Close:
$1.09
Open:
$1.1
24h Volume:
47,276
Relative Volume:
0.86
Market Cap:
$3.82M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-0.2115
EPS:
-5.2
Net Cash Flow:
$-9.42M
1W Performance:
+27.14%
1M Performance:
+56.36%
6M Performance:
-46.60%
1Y Performance:
-68.79%
1-Day Range:
$1.02
$1.11
1-Week Range:
$0.7995
$1.11
52-Week Range:
$0.613
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.10 | 3.78M | 0 | -9.29M | -9.42M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.70 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.66 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
867.30 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.70 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.25 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
SCNI | Scinai Immunotherapeutics Ltd. ADR SEC Filings - MarketWatch
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai Immunotherapeutics schedules annual meeting for December 22 By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView
Scinai receives $246,000 grant to expand biotech manufacturing By Investing.com - Investing.com South Africa
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports First-Half 2025 Results, Strengthened Cash Position - Barchart.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Barchart.com
Scinai Immunotherapeutics (NASDAQ:SCNI) Trading Down 3.8% – Here’s What Happened - Defense World
Scinai Immunotherapeutics (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier - Barchart.com
Scinai Immunotherapeutics stock soars on promising skin disease drug data - Investing.com Australia
Scinai’s PC111 antibody shows promise for pemphigus treatment By Investing.com - Investing.com Canada
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com India
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - Benzinga
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Finviz
Augusta Gold (TSE:G) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Finviz
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Announces Annual Financial Results for 2024 - Finviz
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - The Globe and Mail
Scinai Immunotherapeutics (SCNI) Stock Forecast and Price Target 2025 - MarketBeat
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics (SCNI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Scinai Immunotherapeutics Ltd. Sponsored ADR Cash Flow – NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - Barchart.com
Scinai Immunotherapeutics (SCNI) Institutional Ownership 2025 - MarketBeat
SCNI Stock Price and Chart — NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis - MarketBeat
Scinai Immunotherapeutics Ltd Share Price ADR Each Representing 400 Ord Shares SPON - Hargreaves Lansdown
SCNIScinai Immunotherapeutics Ltd ADR Stock Price and Quote - Finviz
What is the current Price Target and Forecast for Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) - Zacks Investment Research
BVXV Financial Statements & ChartsScinai Immunotherapeutics LtdAdr MacroTrends - CMLviz
BVXV Pivot Points, Technical Analysis and Moving AveragesScinai Immunotherapeutics LtdAdr Technicals - CMLviz
SCNI Stock Price | Scinai Immunotherapeutics Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):